Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development. Among these are an oral tablet for norovirus, an oral influenza vaccine, and VXA-CoV2-1, an oral COVID-19 vaccine candidate. Vaxart has reported data from Phase I and Phase II clinical trials demonstrating favorable safety profiles and immune responses that support further clinical evaluation. In addition to its lead programs, Vaxart is exploring applications of its platform for prophylactic and therapeutic vaccines against other respiratory and enteric pathogens.

Headquartered in South San Francisco, California, Vaxart collaborates with academic institutions and government agencies to advance its oral vaccine technology. The company’s management team brings together experienced professionals in vaccine R&D, regulatory affairs, and commercial strategy, guiding Vaxart through clinical and regulatory milestones. By focusing on ease of administration and global distribution, Vaxart seeks to address unmet needs in vaccine access and public health preparedness.

Key Stats

• Today's Range: $0.75 to $0.78
• 50-Day Range: $0.59 to $0.80
• 52-Week Range: $0.26 to $0.84
• Volume: 399,818 shs
• Average Volume: 702,653 shs
• Market Capitalization: $182.69 million
• P/E Ratio: 12.59
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VXRT Stock Analysis - Frequently Asked Questions

How have VXRT shares performed this year?

Vaxart's stock was trading at $0.3464 at the start of the year. Since then, VXRT shares have increased by 118.0% and is now trading at $0.7553.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (OTCMKTS:VXRT) posted its quarterly earnings data on Thursday, March, 12th. The biotechnology company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.32. The biotechnology company earned $104.24 million during the quarter, compared to analysts' expectations of $35.95 million. Vaxart had a trailing twelve-month return on equity of 33.83% and a net margin of 6.88%.
Read the conference call transcript.

When did Vaxart's stock split?

Vaxart shares reverse split before market open on Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 3/12/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 120
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): $0.06
• Trailing P/E Ratio: 12.59
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $16.33 million
• Net Margins: 6.88%
• Pretax Margin: 7.08%
• Return on Equity: 33.83%
• Return on Assets: 9.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $47.40 million
• Price / Sales: 3.85
• Cash Flow: $0.10 per share
• Price / Cash Flow: 7.52
• Book Value: $0.37 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 241,973,000
• Free Float: 235,198,000
• Market Cap: $182.69 million
• Optionable: No Data
• Beta: 1.18